Monte Rosa Therapeutics
@monterosatx.com
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more.
Our CMO, Filip Janku, will participate in a virtual fireside chat at the TD Cowen Immunology & Inflammation Summit to discuss how we're advancing our I&I portfolio.
Register or view the webcast: bit.ly/4p8Inx1
Register or view the webcast: bit.ly/4p8Inx1
November 13, 2025 at 1:16 PM
Our CMO, Filip Janku, will participate in a virtual fireside chat at the TD Cowen Immunology & Inflammation Summit to discuss how we're advancing our I&I portfolio.
Register or view the webcast: bit.ly/4p8Inx1
Register or view the webcast: bit.ly/4p8Inx1
ICYMI: We presented preclinical data at #AHA2025 showing that degrading NEK7 to modulate the NLRP3 inflammasome offers a novel, differentiated approach with potential in cardiovascular and cardiometabolic diseases.
Learn more: bit.ly/3XjONNQ
Learn more: bit.ly/3XjONNQ
November 11, 2025 at 1:00 PM
ICYMI: We presented preclinical data at #AHA2025 showing that degrading NEK7 to modulate the NLRP3 inflammasome offers a novel, differentiated approach with potential in cardiovascular and cardiometabolic diseases.
Learn more: bit.ly/3XjONNQ
Learn more: bit.ly/3XjONNQ
CEO Markus Warmuth shares his perspective on the future of Monte Rosa and molecular glue degraders in a fireside chat today at the Guggenheim 2nd Annual Healthcare Innovation Conference.
To register: bit.ly/4qIpZwq
To register: bit.ly/4qIpZwq
November 10, 2025 at 1:00 PM
CEO Markus Warmuth shares his perspective on the future of Monte Rosa and molecular glue degraders in a fireside chat today at the Guggenheim 2nd Annual Healthcare Innovation Conference.
To register: bit.ly/4qIpZwq
To register: bit.ly/4qIpZwq
Today, we present preclinical data on the potential of MRT-8102, a first-in-class, NEK7-directed MGD for inflammatory diseases driven by the NLRP3 inflammasome at AHA Scientific Sessions 2025.
Learn more: bit.ly/43SJQiF
#AHA2025
Learn more: bit.ly/43SJQiF
#AHA2025
November 8, 2025 at 4:38 PM
Today, we present preclinical data on the potential of MRT-8102, a first-in-class, NEK7-directed MGD for inflammatory diseases driven by the NLRP3 inflammasome at AHA Scientific Sessions 2025.
Learn more: bit.ly/43SJQiF
#AHA2025
Learn more: bit.ly/43SJQiF
#AHA2025
Today, we report financial results and business highlights for the third quarter 2025. Read more: bit.ly/43f5vBo
November 6, 2025 at 12:23 PM
Today, we report financial results and business highlights for the third quarter 2025. Read more: bit.ly/43f5vBo
ICYMI: our team presented data at #ACR25 showing MRT-6160, a first-in-class VAV1-directed MGD, inhibited disease pathology in a preclinical autoimmune model. CSO Sharon Townson shares perspective on the significance of these findings.
View the poster: bit.ly/3L955q7
View the poster: bit.ly/3L955q7
October 27, 2025 at 12:04 PM
ICYMI: our team presented data at #ACR25 showing MRT-6160, a first-in-class VAV1-directed MGD, inhibited disease pathology in a preclinical autoimmune model. CSO Sharon Townson shares perspective on the significance of these findings.
View the poster: bit.ly/3L955q7
View the poster: bit.ly/3L955q7
At #ACR25? Join Marisa Peluso as she presents the latest preclinical data on the potential of MRT-6160, a VAV1-directed molecular glue degrader, to treat immune-mediated diseases.
Read the full press release here: bit.ly/4o7koyf
Read the full press release here: bit.ly/4o7koyf
October 24, 2025 at 11:04 AM
At #ACR25? Join Marisa Peluso as she presents the latest preclinical data on the potential of MRT-6160, a VAV1-directed molecular glue degrader, to treat immune-mediated diseases.
Read the full press release here: bit.ly/4o7koyf
Read the full press release here: bit.ly/4o7koyf
Proud to be recognized among the “Six Targeted Protein Degrader Companies to Watch” by @clarivatelsh.bsky.social.
Learn more about our pioneering work in molecular glue degraders and download the full report here: bit.ly/4odvdye
Learn more about our pioneering work in molecular glue degraders and download the full report here: bit.ly/4odvdye
October 10, 2025 at 12:03 PM
Proud to be recognized among the “Six Targeted Protein Degrader Companies to Watch” by @clarivatelsh.bsky.social.
Learn more about our pioneering work in molecular glue degraders and download the full report here: bit.ly/4odvdye
Learn more about our pioneering work in molecular glue degraders and download the full report here: bit.ly/4odvdye
Adam Cartwright presents preclinical data today at #ECTRIMS2025 suggesting MRT-6160, a first-in-class VAV1-directed MGD, has the potential to benefit patients with neuroinflammatory diseases as well as other T- and B-cell immune-mediated conditions: bit.ly/3KEi7vf
September 25, 2025 at 11:14 AM
Adam Cartwright presents preclinical data today at #ECTRIMS2025 suggesting MRT-6160, a first-in-class VAV1-directed MGD, has the potential to benefit patients with neuroinflammatory diseases as well as other T- and B-cell immune-mediated conditions: bit.ly/3KEi7vf
David Wild of In Vivo had an insightful conversation with our CEO, Markus Warmuth, and CDIO, John Castle, about the past, present, and future of Monte Rosa, and the broad, growing potential of molecular glues. Read more [note that content is paywalled]: bit.ly/4gEiIJB
September 24, 2025 at 1:15 PM
David Wild of In Vivo had an insightful conversation with our CEO, Markus Warmuth, and CDIO, John Castle, about the past, present, and future of Monte Rosa, and the broad, growing potential of molecular glues. Read more [note that content is paywalled]: bit.ly/4gEiIJB
This week’s announcement of a second collaboration with @novartis.bsky.social includes an exclusive license to an undisclosed discovery target and options to license two preclinical immunology programs.
CEO Markus Warmuth comments: bit.ly/3Vl0yTg
CEO Markus Warmuth comments: bit.ly/3Vl0yTg
September 16, 2025 at 12:02 PM
This week’s announcement of a second collaboration with @novartis.bsky.social includes an exclusive license to an undisclosed discovery target and options to license two preclinical immunology programs.
CEO Markus Warmuth comments: bit.ly/3Vl0yTg
CEO Markus Warmuth comments: bit.ly/3Vl0yTg
Today we announced our second collaboration with @novartis.bsky.social to develop novel degraders for immune-mediated diseases. Given the strong progress we’ve made on our collaboration advancing VAV1 degraders, we’re thrilled to be collaborating with them again: bit.ly/3Vl0yTg
September 15, 2025 at 11:08 AM
Today we announced our second collaboration with @novartis.bsky.social to develop novel degraders for immune-mediated diseases. Given the strong progress we’ve made on our collaboration advancing VAV1 degraders, we’re thrilled to be collaborating with them again: bit.ly/3Vl0yTg
At this year’s 2025 Stifel I&I Forum, our CEO, Markus Warmuth, will participate in a fireside chat and provide an overview of our I&I pipeline progress. Learn more: bit.ly/41PXdiR
September 12, 2025 at 12:01 PM
At this year’s 2025 Stifel I&I Forum, our CEO, Markus Warmuth, will participate in a fireside chat and provide an overview of our I&I pipeline progress. Learn more: bit.ly/41PXdiR
As part of this year’s Dana-Farber TPD Webinar series, Georg Petzold will present on how we’ve upended the paradigm of what is possible with cereblon-based molecular glue degraders. We hope you can join! www.danafarbertargetedproteindegradation.org
September 10, 2025 at 12:02 PM
As part of this year’s Dana-Farber TPD Webinar series, Georg Petzold will present on how we’ve upended the paradigm of what is possible with cereblon-based molecular glue degraders. We hope you can join! www.danafarbertargetedproteindegradation.org
John Castle sat down with Jim Cornall of LabiotechEU to discuss how our team and AI-driven QuEEN™ discovery engine are redefining what’s possible with molecular glues. The episode aired on Freddie Mercury’s birthday. Give it a listen, it will “Rock You”! bit.ly/3IbPNQ7
September 8, 2025 at 12:00 PM
John Castle sat down with Jim Cornall of LabiotechEU to discuss how our team and AI-driven QuEEN™ discovery engine are redefining what’s possible with molecular glues. The episode aired on Freddie Mercury’s birthday. Give it a listen, it will “Rock You”! bit.ly/3IbPNQ7
Learn more about the people, passion and precision shaping the future of targeted protein degradation: bit.ly/4mhJDNf
August 19, 2025 at 12:17 PM
Learn more about the people, passion and precision shaping the future of targeted protein degradation: bit.ly/4mhJDNf
August is Autoinflammatory Awareness Month – a time to elevate understanding of immune-driven conditions.
At Monte Rosa, we’re advancing science in immunology and inflammation to help bring forward new options for patients: bit.ly/4fyevqj
@autoinflammatory.bsky.social
At Monte Rosa, we’re advancing science in immunology and inflammation to help bring forward new options for patients: bit.ly/4fyevqj
@autoinflammatory.bsky.social
August 12, 2025 at 12:10 PM
August is Autoinflammatory Awareness Month – a time to elevate understanding of immune-driven conditions.
At Monte Rosa, we’re advancing science in immunology and inflammation to help bring forward new options for patients: bit.ly/4fyevqj
@autoinflammatory.bsky.social
At Monte Rosa, we’re advancing science in immunology and inflammation to help bring forward new options for patients: bit.ly/4fyevqj
@autoinflammatory.bsky.social
Today, we report financial results and business highlights for the second quarter 2025. Read more: bit.ly/45pOnJC
August 7, 2025 at 12:06 PM
Today, we report financial results and business highlights for the second quarter 2025. Read more: bit.ly/45pOnJC
Thanks to Alex Eccleston of Nature Reviews Drug Discovery for a very nice summary of our recent Science Magazine publication. If you don’t have time to read the full paper, make the time! Or read this summary, which provides a great overview. www.nature.com/articles/d41...
Broader horizons for cereblon glue degraders
Discover the world’s best science and medicine | Nature.com
www.nature.com
August 4, 2025 at 12:01 PM
Thanks to Alex Eccleston of Nature Reviews Drug Discovery for a very nice summary of our recent Science Magazine publication. If you don’t have time to read the full paper, make the time! Or read this summary, which provides a great overview. www.nature.com/articles/d41...
A big thank you to our fantastic 2025 interns, who include Lauren Brooks, Ramya Naraharisetti, Amit Pandey, Enea Pinchetti, and Mathilde Hemery! We’re grateful for their excellent work and the insights they share here on their experiences at Monte Rosa. #NationalInternDay
July 31, 2025 at 2:34 PM
A big thank you to our fantastic 2025 interns, who include Lauren Brooks, Ramya Naraharisetti, Amit Pandey, Enea Pinchetti, and Mathilde Hemery! We’re grateful for their excellent work and the insights they share here on their experiences at Monte Rosa. #NationalInternDay
We’re excited to announce the first subjects have been dosed in a Phase 1 study of MRT-8102, a NEK7-directed MGD being developed for inflammatory conditions linked to the NLRP3 inflammasome, IL-1β, and IL-6.
Learn more: bit.ly/4m5JOe7
Learn more: bit.ly/4m5JOe7
July 21, 2025 at 11:59 AM
We’re excited to announce the first subjects have been dosed in a Phase 1 study of MRT-8102, a NEK7-directed MGD being developed for inflammatory conditions linked to the NLRP3 inflammasome, IL-1β, and IL-6.
Learn more: bit.ly/4m5JOe7
Learn more: bit.ly/4m5JOe7
Exceptional individuals united as a team are critical to our success. Join us on our epic journey from one of two base camps – Boston and Basel. To view open positions, visit: bit.ly/44yYQmP
July 16, 2025 at 11:56 AM
Exceptional individuals united as a team are critical to our success. Join us on our epic journey from one of two base camps – Boston and Basel. To view open positions, visit: bit.ly/44yYQmP
Grateful to Sally Church for her incisive review of our recent @science.org manuscript, capturing its significance — from target space expansion to pharmacologic implications to the evolving therapeutic landscape. @maverickny.bsky.social
biotechstrategyblog.com/2025/07/how-...
biotechstrategyblog.com/2025/07/how-...
How Monte Rosa just rewrote the Degrader Playbook | Biotech Strategy Blog
biotechstrategyblog.com
July 11, 2025 at 12:39 PM
Grateful to Sally Church for her incisive review of our recent @science.org manuscript, capturing its significance — from target space expansion to pharmacologic implications to the evolving therapeutic landscape. @maverickny.bsky.social
biotechstrategyblog.com/2025/07/how-...
biotechstrategyblog.com/2025/07/how-...
Sharon Townson and John Castle comment on our groundbreaking work recently featured on the cover of Science Magazine, @science.org.
We’ve shown the molecular glue target space is broader than previously understood, and we believe we are uniquely positioned to harness its potential: bit.ly/4koxZ1m
We’ve shown the molecular glue target space is broader than previously understood, and we believe we are uniquely positioned to harness its potential: bit.ly/4koxZ1m
July 8, 2025 at 12:23 PM
Sharon Townson and John Castle comment on our groundbreaking work recently featured on the cover of Science Magazine, @science.org.
We’ve shown the molecular glue target space is broader than previously understood, and we believe we are uniquely positioned to harness its potential: bit.ly/4koxZ1m
We’ve shown the molecular glue target space is broader than previously understood, and we believe we are uniquely positioned to harness its potential: bit.ly/4koxZ1m
ICYMI: Last week, we published discoveries in a Science Magazine (@science.org) cover story that enable the next generation of molecular glue degrader (MGD) medicines and vastly expand the number of potential targets addressable with MGDs and our QuEEN™ discovery engine.
bit.ly/4kvoGwH
bit.ly/4kvoGwH
July 7, 2025 at 12:25 PM
ICYMI: Last week, we published discoveries in a Science Magazine (@science.org) cover story that enable the next generation of molecular glue degrader (MGD) medicines and vastly expand the number of potential targets addressable with MGDs and our QuEEN™ discovery engine.
bit.ly/4kvoGwH
bit.ly/4kvoGwH